Disease-Free Survival

More than 20% of BRCA mutation carriers became pregnant within 10 years after receiving an early breast cancer diagnosis, and pregnancy did not affect disease-free survival, researchers reported in JAMA.

CHICAGO — Aspirin was not linked to a benefit in invasive disease-free survival, according to updated study results presented at ASCO Annual Meeting.

A regimen of neoadjuvant nab-paclitaxel with carboplatin may be an effective anthracycline-free treatment with an acceptable pathological complete response rate among triple negative breast cancer patients with BCRA1/2 mutations, according to research presented at ASCO 2021.

In this video, Holly Pederson, MD, assistant professor of medicine in the Cleveland Clinic Lerner College of Medicine of Case Western University, spoke with Healio about results from the OlympiA trial presented at ASCO 2021.